<DOC>
	<DOCNO>NCT01361763</DOCNO>
	<brief_summary>This study Phase II , randomize , crossover trial design compare one fix dose dabigatran open-label use ASA patient affect CADASIL ; study safety trial , primary objective ass dabigatran less safe ASA subject CADASIL .</brief_summary>
	<brief_title>Safety Study Dabigatran CADASIL</brief_title>
	<detailed_description>The primary endpoint number microbleeds , measure MRI , 90 day follow . The study base hypothesis drug inhibitor thrombin effective ASA prevent vessel obstruction . The rationale behind study base assumption : ) formation microthrombi relevant clinical expression CADASIL disease , b ) thrombin inhibitor effective antiplatelet drug prevent lesion microvessel obstruction . Eligible patient randomize one 2 treatment group : 1 . One week wash-out ( W1 ) , Dabigatran one tablet 100mg twice day 12 week , second one week wash-out ( W2 ) , treatment ASA one tablet 100mg/day day 12 week ; 2 . The scheme repeat reversed sequence No initial wash-out week require patient group 2 already treat ASA . Clinical instrumental evaluation carry first ( W1 ) second wash-out week ( W2 ) , end study ( week follow second treatment regimen ( W3 ) . Each evaluation consist physical examination , blood test MRI . Safety evaluate basis brain microbleeds severe haemorrhage .</detailed_description>
	<mesh_term>CADASIL</mesh_term>
	<mesh_term>Dementia , Multi-Infarct</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Patients age 18 year old diagnose CADASIL accord genetic test eligible . Treatment antiplatelet drug condition different CADASIL ; condition associate increase risk bleeding ( major surgery within previous month , plan surgery intervention within next 3 month ; history intracranial , intraocular , spinal , retroperitoneal atraumatic intra‚Äêarticular bleeding ; gastrointestinal hemorrhage within past year ; symptomatic endoscopically document gastroduodenal ulcer disease previous 30 day ; hemorrhagic disorder bleed diathesis ; need anticoagulant treatment disorder atrial fibrillation ; fibrinolytic agent within 48 hour study entry ; uncontrolled hypertension ( systolic blood pressure great 180 mm Hg and/or diastolic blood pressure great 100 mm Hg ) ; recent malignancy radiation therapy ( within 6 month ) expect survive 3 year ; severe renal impairment ( estimate creatinine clearance 30 mL/min less ) ; active infective endocarditis ; active liver disease ( include limit persistent ALT , AST , Alk Phos great twice upper limit normal range ; active hepatitis C ( positive HCV RNA ) ; active hepatitis B ( HBs antigen + , anti HBc IgM + ) , active hepatitis A ) ; woman pregnant childbearing potential refuse use medically acceptable form contraception throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Dabigatran</keyword>
	<keyword>Microbleeds</keyword>
	<keyword>Microthrombi</keyword>
	<keyword>CADASIL</keyword>
	<keyword>Small Vessel Disease</keyword>
</DOC>